A randomized trial to compare 7- and 21-day tetracycline regimens in the prevention of recurrence of infection with chlamydia trachomatis

Barry Katz, Virginia A. Caine, Byron Batteiger, Robert B. Jones

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Standard therapy for Chlamydia trachomatis in the United States consists of a 7-day course of tetracycline administration. Recurrent infections are frequent, however, in circumstances in which reinfection seems unlikely, suggesting that the standard regimen may be insufficient to cure the infection. It may reduce the number of organisms, however, below a detectable level at a test-of-cure visit. To evaluate recurrent infection, the authors studied patients with chlamydia who were treated with standard therapy, and they found a recurrence rate of 29% among 2,983 patients who returned to the clinic during a 2-year follow-up period. Recurrent infection was associated with younger age but was not related to either race or gender. To test the hypothesis that a longer treatment course might be more effective in preventing recurrent infection, the authors conducted a randomized trial that compared 7- and 21-day regimens of tetracycline administration. Of the 918 subjects enrolled in the trial, 220 were infected with C. trachomatis. The overall recurrence rate among patients who were infected and returned was 18.4% (9/49) in the 21-day group and 13.8% (8/58) in the 7-day group (P =.60). Similar results were obtained using survival analysis methods. Given the number of subjects who returned, this study had approximately a 65% statistical power to detect a reduction in recurrence rate, from 20% to 5%. Because of the similarity of the results in the two groups, it was concluded that 21 days of tetracycline administration is no more effective in preventing recurrence than 7 days of administration.

Original languageEnglish
Pages (from-to)36-40
Number of pages5
JournalSexually Transmitted Diseases
Volume18
Issue number1
StatePublished - 1991

Fingerprint

Chlamydia trachomatis
Tetracycline
Recurrence
Infection
Chlamydia
Survival Analysis
Therapeutics

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases
  • Microbiology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

A randomized trial to compare 7- and 21-day tetracycline regimens in the prevention of recurrence of infection with chlamydia trachomatis. / Katz, Barry; Caine, Virginia A.; Batteiger, Byron; Jones, Robert B.

In: Sexually Transmitted Diseases, Vol. 18, No. 1, 1991, p. 36-40.

Research output: Contribution to journalArticle

@article{26da5ff615de424dab37b55c916674c0,
title = "A randomized trial to compare 7- and 21-day tetracycline regimens in the prevention of recurrence of infection with chlamydia trachomatis",
abstract = "Standard therapy for Chlamydia trachomatis in the United States consists of a 7-day course of tetracycline administration. Recurrent infections are frequent, however, in circumstances in which reinfection seems unlikely, suggesting that the standard regimen may be insufficient to cure the infection. It may reduce the number of organisms, however, below a detectable level at a test-of-cure visit. To evaluate recurrent infection, the authors studied patients with chlamydia who were treated with standard therapy, and they found a recurrence rate of 29{\%} among 2,983 patients who returned to the clinic during a 2-year follow-up period. Recurrent infection was associated with younger age but was not related to either race or gender. To test the hypothesis that a longer treatment course might be more effective in preventing recurrent infection, the authors conducted a randomized trial that compared 7- and 21-day regimens of tetracycline administration. Of the 918 subjects enrolled in the trial, 220 were infected with C. trachomatis. The overall recurrence rate among patients who were infected and returned was 18.4{\%} (9/49) in the 21-day group and 13.8{\%} (8/58) in the 7-day group (P =.60). Similar results were obtained using survival analysis methods. Given the number of subjects who returned, this study had approximately a 65{\%} statistical power to detect a reduction in recurrence rate, from 20{\%} to 5{\%}. Because of the similarity of the results in the two groups, it was concluded that 21 days of tetracycline administration is no more effective in preventing recurrence than 7 days of administration.",
author = "Barry Katz and Caine, {Virginia A.} and Byron Batteiger and Jones, {Robert B.}",
year = "1991",
language = "English",
volume = "18",
pages = "36--40",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A randomized trial to compare 7- and 21-day tetracycline regimens in the prevention of recurrence of infection with chlamydia trachomatis

AU - Katz, Barry

AU - Caine, Virginia A.

AU - Batteiger, Byron

AU - Jones, Robert B.

PY - 1991

Y1 - 1991

N2 - Standard therapy for Chlamydia trachomatis in the United States consists of a 7-day course of tetracycline administration. Recurrent infections are frequent, however, in circumstances in which reinfection seems unlikely, suggesting that the standard regimen may be insufficient to cure the infection. It may reduce the number of organisms, however, below a detectable level at a test-of-cure visit. To evaluate recurrent infection, the authors studied patients with chlamydia who were treated with standard therapy, and they found a recurrence rate of 29% among 2,983 patients who returned to the clinic during a 2-year follow-up period. Recurrent infection was associated with younger age but was not related to either race or gender. To test the hypothesis that a longer treatment course might be more effective in preventing recurrent infection, the authors conducted a randomized trial that compared 7- and 21-day regimens of tetracycline administration. Of the 918 subjects enrolled in the trial, 220 were infected with C. trachomatis. The overall recurrence rate among patients who were infected and returned was 18.4% (9/49) in the 21-day group and 13.8% (8/58) in the 7-day group (P =.60). Similar results were obtained using survival analysis methods. Given the number of subjects who returned, this study had approximately a 65% statistical power to detect a reduction in recurrence rate, from 20% to 5%. Because of the similarity of the results in the two groups, it was concluded that 21 days of tetracycline administration is no more effective in preventing recurrence than 7 days of administration.

AB - Standard therapy for Chlamydia trachomatis in the United States consists of a 7-day course of tetracycline administration. Recurrent infections are frequent, however, in circumstances in which reinfection seems unlikely, suggesting that the standard regimen may be insufficient to cure the infection. It may reduce the number of organisms, however, below a detectable level at a test-of-cure visit. To evaluate recurrent infection, the authors studied patients with chlamydia who were treated with standard therapy, and they found a recurrence rate of 29% among 2,983 patients who returned to the clinic during a 2-year follow-up period. Recurrent infection was associated with younger age but was not related to either race or gender. To test the hypothesis that a longer treatment course might be more effective in preventing recurrent infection, the authors conducted a randomized trial that compared 7- and 21-day regimens of tetracycline administration. Of the 918 subjects enrolled in the trial, 220 were infected with C. trachomatis. The overall recurrence rate among patients who were infected and returned was 18.4% (9/49) in the 21-day group and 13.8% (8/58) in the 7-day group (P =.60). Similar results were obtained using survival analysis methods. Given the number of subjects who returned, this study had approximately a 65% statistical power to detect a reduction in recurrence rate, from 20% to 5%. Because of the similarity of the results in the two groups, it was concluded that 21 days of tetracycline administration is no more effective in preventing recurrence than 7 days of administration.

UR - http://www.scopus.com/inward/record.url?scp=0025831545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025831545&partnerID=8YFLogxK

M3 - Article

C2 - 2028366

AN - SCOPUS:0025831545

VL - 18

SP - 36

EP - 40

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 1

ER -